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Abstract
Purpose of Review Hypertension is recognised as the biggest contributor to the global burden of disease, but it is controlled in
less than a fifth of patients worldwide, despite being relatively easy to detect and the availability of inexpensive safe generic
drugs. Blood pressure is regulated by a complex network of physiologic pathways with currently available drugs targeting key
receptors or enzymes in the top pathways. Major advances in the dissection of both monogenic and polygenic determinants of
blood pressure regulation and variation have not resulted in rapid translation of these discoveries into clinical applications or
precision medicine.
Recent Findings Uromodulin is an example of a novel gene for hypertension identified from genome-wide association studies,
currently the basis of a clinical trial to reposition loop diuretics in hypertension management. Gene-editing studies have
established a genome-wide association studies (GWAS) SNP in chromosome 6p24, implicated in six conditions including
hypertension, as a distal regulator of the endothelin-1 gene around 3000 base pairs away. Genomics of aldosterone-producing
adenomas bring to focus the paradox in genomic medicine where availability of cheap generic drugs may render precision
medicine uneconomical.
Summary The speed of technology-driven genomic discoveries and the sluggish traditional pathways of drug development and
translation need harmonisation to make a timely and early impact on global public health. This requires a directed collaborative
effort for which we propose a hypertension moonshot to make a quantum leap in hypertension management and cardiovascular
risk reduction by bringing together traditional bioscience, omics, engineering, digital technology and data science.
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Introduction
Blood pressure (BP) is regulated by a complex network of
interacting pathways involving renal, neural, endocrine,
vascular and other mechanisms along with multiple envi-
ronmental factors. Multiple genes within each of these
systems contribute to BP regulation and the identification
of these variants, their effects and potential targets for
drugs has been the goal of genetic studies of BP and
hypertension. Hypertension is the single largest cause of
mortality worldwide and the public health challenges in
reducing the burden of hypertension require new discov-
eries for both detection and treatment. Genomic studies
have taken precedence over other discovery sciences in
trying to address these challenges. The key reasons are
that the genome essentially remains unchanged through-
out life, genomic variations that influence gene function
and thence phenotype have the potential to be targeted by
drugs and finally, the rapid revolution in high-throughput
genomics in the last 20 years. In this review, we assess the
role of genomics of hypertension in the context of current
discoveries and focus on four exemplars where whole
genome studies are advancing our knowledge of BP reg-
ulation with potential early clinical applications. We
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finally discuss what is required to move discovery to clin-
ical implementation with demonstrable early and tangible
impact on public health.
SNPs—‘Drinking From the Fire Hose’
The era of genome-wide association studies (GWAS) com-
menced in 2007, resulting in a torrent of GWAS for a wide
range of polygenic traits including hypertension and BP. The
hypothesis underlying GWAS is that common variations
(SNPs) can have significant impact on common traits and
thence human health. Currently, there are over 500 SNPs as-
sociated with BP and hypertension [1••] with more likely to be
identified when the full value of the UK Bio-Bank genetic
data is harnessed. The scale and rate of SNP associations for
BP (and for other similar polygenic traits) have been likened
to ‘drinking from the fire hose’ [2••]. Soon, we expect an
acceleration in identification of even more genomic signals
from the combination of whole-genome and omics studies
on millions of individuals. The ‘drinking from the fire hose’
analogy is as relevant today as it was in 2007 and highlights
the reality of modern genomic studies where physicians and
scientists try to keep up with exponential growth in genetic
discoveries. The ultimate goal of any genetic study is clinical
translation and application. However, technically, GWAS is
not designed to inform clinical practice directly in the doctor’s
office. It is designed to explore genetic architecture at a pop-
ulation level and not at an individual level. Furthermore, the
results of GWAS studies do not directly yield a causal gene
target or mechanism. This results in an inevitable time lag
between GWAS discoveries progressing through underpin-
ning biological studies followed by clinical translation. Most
common traits including hypertension demonstrate a handful
of early promising functional signals which are the ‘low hang-
ing fruit’ of potentially translatable signals amongst the hun-
dreds of GWAS signals. In a recent review, overlaying the
clinical, therapeutic and molecular genetic timelines of hyper-
tension understanding and scientific progress highlighted
three points—(i) hypertension and its complications has been
recognised over 2000 years ago; (ii) despite major advances in
unravelling the molecular determinants of monogenic forms
of hypertension, these have not informed new drug discover-
ies, and (iii) anti-hypertensive drugs used currently target most
of the pathways involved in monogenic hypertension and
there have been no new molecular targets for hypertension
identified in the last decade [3]. The explosion of genetic
discoveries from genomic studies (GWAS, exome and whole
genome studies) is likely to catalyse the next era in BP pre-
vention, detection andmanagement. The biggest bottleneck so
far has been linking GWAS SNPs to biology, and this is slow
despite recent efforts such as ENCODE [4], Epigenome Road
Map [5], and GTEx [6] allowing functional exploration of risk
variants at genome-wide scale. Though most genetic studies,
so far, have focussed on single variant associations, and not on
epistasis or gene-environment interactions, there are now ef-
forts to extend studies on these domains. Such studies may
identify more new signals, but more importantly bring the
environment aspect into consideration (Fig. 1).
GWAS SNP to Clinical Trial
A GWAS for hypertension using an extreme case-control de-
sign identified a SNP in the 5′ region of uromodulin gene
(UMOD), which is almost exclusively expressed in the thick
ascending limb of the loop of Henle in the kidney. This study
identified a potentially novel pathway of BP regulation, which
acts through an effect on sodium homeostasis [7]. Moreover,
independent studies have identified SNPs highly correlated
with the hypertension SNP near UMOD to be associated with
chronic kidney disease [8]. Trudu et al. [9] showed that furo-
semide treatment significantly enhanced natriuresis and re-
duced BP levels both in the transgenic mice and in the hyper-
tensive individuals homozygous for the UMOD increasing
allele, making this a potentially interesting locus for both hy-
pertension and renal disease [7–9]. This is now the basis of a
clinical trial (www.clinicaltrials.govNCT03354897) to
reposition a loop diuretic in the hypertension care pathway.
Novel Pathways with Potential Translation
The vascular endothelium synthesises and releases a spectrum
of vasoactive substances, including nitric oxide (NO), a potent
vasodilator. Other vascular relaxation factors include
endothelins and prostacyclin. Endothelin-1 (EDN1) activates
specific ETA receptors (EDNRA) on vascular smooth muscle
cells to cause vasoconstriction and cell proliferation. In con-
trast, endothelial ETB receptors (EDNRB) mediate vasodila-
tation via release of NO and prostacyclin (PGI2). A GWAS of
coronary artery disease (CAD) showed the SNP rs9349379 G
allele (frequency 36%) was associated with increased risk of
CAD and coronary calcification but decreased risk for four
conditions (migraine headache, cervical artery dissection,
fibromuscular dysplasia and hypertension [10, 11]). This
SNP is located within the third intron of the gene encoding
phosphatase and actin regulatory protein 1 (PHACTR1).
However, functional analysis of this variant showed that it
regulates expression of endothelin 1 (EDN1), a gene located
600 kb upstream of PHACTR1. This result was obtained using
the new CRISPR/Cas9 gene-editing method to delete a small
region of DNA at rs9349379 in human pluripotent stem cells,
which were then converted into vascular cell to study how
rs9349379 regulates the activity of the physically distant
EDN1 gene. Interestingly, variants in the PHACTR1 gene
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have been associated with fibromuscular dysplasia (FMD), a
non-atherosclerotic vascular disease leading to stenosis, dis-
sections and aneurysms affecting mainly the renal and cere-
brovascular arteries [12]. This study highlights the complexity
of functional analysis of GWAS signals and the value of es-
tablishing the true causal gene linked to the GWAS signal.
Endothelin receptor antagonists were discovered in the
1980s and are now used in the treatment of pulmonary hyper-
tension. The early trials for hypertension treatment were not
encouraging, but it is clear that greater understanding of
endothelin regulation from genomic studies may inform future
targeted use of endothelin antagonists in the treatment of
hypertension.
Aldosteronism
Aldosterone-producing adenomas (APAs) are found in 1.5–
3.0% of hypertensive patients in primary care and can be
cured by surgery. Elucidation of genetic events may improve
our understanding of these tumours and ultimately improve
patient care. A gain-of-function somatic mutation in a K+
channel, KCNJ5, which results in membrane depolarization
and enhanced aldosterone production, is a common genetic
defect noted for ~ 40% of APAs. Mutations in three other
genes, encoding the α-subunit of Na+-K+-ATPase itself; the
ATP2B3, a plasma membrane Ca2+-ATPase homologous to
the sarcoplasmic endoplasmic reticulum Ca2+-ATPases
(SERCA); and CACNA1D, encoding an L-type Ca2+ channel
CaV1.3, are observed in ~ 7% of the cases [13]. Whereas
APAs in adrenal zona glomerulosa cells harbour gain-of-
function mutations in genes important for the regulation of
Na+ and Ca2+-, ATP1A1 and CACNA1D, respectively,
KCNJ5 mutations are common in APAs resembling cortisol-
secreting cells of the adrenal zona fasciculata [14••].
Adenomas with KCNJ5 mutations are typical of Conn’s
adenoma and tend to be larger than other tumours with
fasciculata-like features by histopathology and gene expres-
sion analysis, whilst CACNA1D and ATP1A1 mutations ap-
pear to be associated with a glomerulosa-like phenotype and
are more likely to be diagnosed in older men with resistant
hypertension [15, 16]. The case of APAs brings to focus a
paradox in genomics medicine, the availability of a specific
and cheap pharmacologic antagonist of aldosterone,
spironolactone, and benign nature of APAs, create a hurdle
to embarking on the expensive investigations and surgery,
which at best offers 30 to 60% likelihood of curing hyperten-
sion [14••].
Mood Disorders and Hypertension Genetics
Although a large body of work has identified associations
between mood disorders and cardio-metabolic diseases (such
as coronary heart disease and diabetes), the relationship be-
tween major depressive disorder/bipolar disorder (MDD/BD)
and hypertension has been much less studied. There is how-
ever now good evidence of pathophysiological overlap be-
tweenMDD/BD and hypertension. In clinical practice, chang-
es in mood (both depressive and manic) have long been
recognised as side effects of some anti-hypertensive medica-
tions [17] and recent epidemiological work has identified that
hypertension is a common comorbidity for individuals with
MDD and BD [18]. Furthermore, recent GWASs have
established that a locus containing the gene CACNA1C (cod-
ing for a subunit of the L-type calcium channel) is a risk factor
for BD [19, 20]. Similarly, CACNB2, also a voltage-gated
calcium channel, is a risk factor for both mood disorders and
hypertension. The pathophysiology of hypertension has there-
fore emerged as an important new potential avenue for devel-
oping novel treatment approaches for mood disorders. For
example, a recent pilot investigation of the L-type calcium-
Fig. 1 Hypertension clinical, therapeutic and genomic timeline. Current
hypertension pharmacotherapy whilst not informed by genomics does
target many of the pathways involved in monogenic BP syndromes.
The timeline highlights the potential of the modern genomics era for
discovery of novel pathways and new drugs for hypertension
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channel blocker Isradipine suggested that it may be effective
for bipolar depression [21]. There is also now good evidence
from animal models that drugs acting on the renin-angiotensin
system (such as ACE-inhibitors) have antidepressant proper-
ties [22]. Using data on 144,066 patients from the Glasgow
Blood Pressure Clinic Cohort, we recently identified that treat-
ment with ACE inhibitors or angiotensin receptor blockers
(ARB) (compared to other classes of anti-hypertensives) is
associated with significantly lower rates of new-onset hospital
admission for mood disorders [23].
Genetic Risk Prediction
Summarising the plethora of genetic findings into a single
metric is attractive as it potentially produces an individual risk
score that could inform personalised treatment or prevention.
A polygenic genotype risk score (GRS) is calculated from
GWAS summary statistics by summing the number of risk
alleles carried by an individual, weighted by the GWAS effect
size. The GRS, by summarising several million genotyped
and imputed common genetic variants into a single variable
for an individual, is very attractive because of the potential for
risk prediction and individualised preventive measures. By
rescaling GRS to have a mean of 0 and a standard deviation
of 1, an individual’s GRS can be converted to quantiles that
enable separation of groups with the highest and lowest risks.
The GRS of the majority of individuals will be close to the
population mean, implying that their predicted risk will be
close to the population lifetime disease risk. It is also pertinent
to note that the relative risk estimates of GWAS SNPs and
GRS are generally < 2 which signifies trivial clinical utility
of these with no real relevance to either screening and diag-
nostic tests, and hence, the realistic conclusion that GRS is not
particularly informative for an individual.
A possible clinical use of the GRS is in determining where
an individual’s GRS lies on the population distribution. For
example, preventive measures or regular screening or early
treatment may be offered to those individuals in the top 1 or
5% of GRS values, depending on the estimated risk for the
disease and its severity. Two studies, one using CAD GRS
constructed from 50 CAD risk variants [24••] and another
using a GRS constructed from 314 BP risk alleles [25••]
showed that lifestyle factors made a similar contribution irre-
spective of the patient’s genetic profile to CAD risk or BP
respectively. They suggest that lifestyle measures offer the
same benefit from prevention across genetic risk strata.
However, this interpretation need to be contextualised on three
key issues about lifestyle and prevention—the difficulty in
accurately measuring lifestyle exposure, the extrapolation of
a single time point measure to lifetime exposure and the fact
that lowering BP by lifestyle requires an enormous sustained
voluntary effort by the individual. Nevertheless, these studies
exemplify the progress made in genomics and these small
incremental steps may be the harbinger of major future
advances.
The Case for a Hypertension Moonshot
Hypertension is a study in contrasts. It is the leading single
risk factor for mortality and global burden of disease with
over 1 billion people affected worldwide. The diagnosis of
hypertension is still based on measurement using a cuff
invented in 1896. The revolution in genomics has resulted
in over 500 SNPs associated with BP and over 32 genes
associated with monogenic forms of hypertension which is
still awaiting entry into clinical applications. Hypertension
is one of the diseases whose treatment has been tested by
the largest number of randomised clinical trials. However,
BP-lowering drugs that are effective and inexpensive are
offered to, and regularly used by, only a fraction of the
patients who need them. Pharmaceutical companies have
largely abandoned the search for a “blockbuster” drug.
New drugs and device therapies in development whilst
initially promising have not been able to survive the rigour
of sham-controlled trials so far. Because of costs, even if
successful, they are likely to be directed towards a relative-
ly small minority of the hypertensive population. The dif-
ferential in the apparent plodding rate of progress in hyper-
tension detection and management and the whirlwind of
exploratory, discovery studies from genomics and big data
needs to be reconciled for any meaningful leap in hyper-
tension management and cardiovascular risk reduction.
This necessitates the pace of progress in disparate but es-
sential strands of basic science, digital technology, innova-
tion, evidence generation and synthesis, clinical, public
health and health economic activities to keep pace with
each other. A recognition of the scale of effort required to
solve the hypertension problem is reflected in the
In te rna t iona l Soc ie ty of Hyper tens ion ’s g loba l
synchronised screening campaign which took place for
the first time during May 2017 in over 100 countries and
screened over 1.2 million people (http://maymeasure.com/
about/). Even though this is only a screening programme
with plans to continue annually, identifying a large
proportion of the 1.2 billion hypertensives worldwide
will have implications on the healthcare systems.
Solutions are needed on a number of strands to ensure
that all individuals who become aware of their BP know
what action to take and that this does not unduly burden
overstretched healthcare systems. The challenge is to
develop and implement these solutions on a global scale
quickly. This means making a decade worth of discoveries,
validation, testing and implementation in 5 years or less
which requires a coming together of the empirical, all-
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comers, RCT-informed strategies and individualised,
multi-omics, big data and technology-driven sciences.
Realisation of this goal requires transformative advances
focussed on collecting more patient data and enabling
faster research, better decision support for physicians and
better engagement of patients on a global scale. Thus, there
is a strong case for a ‘hypertension moonshot’ (along the
lines of the cancer moonshot) to accelerate screening, di-
agnosis and management of hypertension. Some of the
challenges for the moonshot include newer ways of mea-
suring BP, use of multidimensional data from wearables in
phenotyping and monitoring, refining the taxonomy of hy-
pertension using omics and big data, functional dissection
and translation of genomic discoveries, and innovative
clinical trials to accelerate clinical implementation from
prediction to treatment. This would require investigators
and stakeholders in biomedical, omics, healthcare, public
health, regulatory, digital technology, engineering and
pharmaceutical domains to work together in an ecosystem
along with patients to identify and overcome bottlenecks.
The gains from this will be immediate rather than in the
distant future, and developing the multi-disciplinary teams
necessary to deliver this over the next 5 years will be an
ambitious but not insurmountable challenge.
Conclusions
As hypertension shows no geographic boundaries, the solu-
tion to mitigate its risk should be global in scope. Advances in
high-throughput genomics have vastly increased our under-
standing of the genetic architecture of BP and hypertension.
The aspiration that this would tangibly improve hypertension
management and thence its public health impact has not yet
been realised. The burgeoning list of genomic variants asso-
ciated with BP and hypertension provides a realistic basis for
refining the molecular taxonomy of hypertension. However,
realistically, any new taxonomy of hypertension should also
incorporate patient characteristics including social, lifestyle
and environmental influences in addition to molecular and
genomic information. Given the global burden of hyperten-
sion, a moonshot initiative is essential to harness expertise and
knowledge in diverse strands to bring about a rapid and pos-
itive impact on global cardiovascular health.
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